News
A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the FDA’s crosshairs for the second time in less than a year. | The FDA has ...
The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...
Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...
While pharmaceuticals have so far been spared from import taxes, Trump has vowed to impose a “major” tariff on the sector ...
Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant’s ...
Eli Lilly has filed a lawsuit against four telehealth platforms selling compounded versions of its blockbuster metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback